Rapid Responses to:
|
|
Rapid Responses: Rapid Responses published:
-
![[Read Rapid Response]](/icons/misc/sectionDOWN.gif)
Regulation of drugs in india
- kasi viswanathan (15 October 2004)
-
Re: Regulation of drugs in india
- Jayashri Sankaranarayanan, Ph.D. (Purdue University) (27 October 2004)
|
|
|||
|
kasi viswanathan, Researcher Bombay
Send response to journal:
|
We should make a policy that when a drug is banned in countries like USA, UK and or Japan, we should stop sale and manufacture, if it is not a very very essential drug. If alternatives are available, we should withhold them immeidately and put under stringent review. If it is very essential for Indians, we should put under restricted use list which should be informed to patients by doctors while prescribing. Competing interests: None declared |
|||
|
|
|||
|
Jayashri Sankaranarayanan, Ph.D. (Purdue University), Assistant Professor University of Nebraska Medical Center, College of Pharmacy, Omaha, NE - 68106-6045
Send response to journal:
|
Regulatory decision making in health sector in India is gradual because the major stakeholder is the private sector and policy decisions require stringent risk benefit reviews. In the presence of banned drugs in the Indian market, it is important to encourage and educate doctors, patients and their families on safe medication use behavior. The patients and their families need to be vigilant of banned drugs and available alternatives in countries like USA, UK, Japan, or the world so that when they are prescribed these drugs they can actively participate in their medical treatment decisions with their doctors and avoid medication errors. The initiative and involvement of doctors, patients and other health professionals like pharmacists and nurses as informed evaluators of medical treatment can improve quality of care and hasten regulatory decision making in India. Competing interests: None declared |
|||